PL1786830T3 - Sposób zatężania przeciwciał i ich produkty lecznicze - Google Patents

Sposób zatężania przeciwciał i ich produkty lecznicze

Info

Publication number
PL1786830T3
PL1786830T3 PL05806393T PL05806393T PL1786830T3 PL 1786830 T3 PL1786830 T3 PL 1786830T3 PL 05806393 T PL05806393 T PL 05806393T PL 05806393 T PL05806393 T PL 05806393T PL 1786830 T3 PL1786830 T3 PL 1786830T3
Authority
PL
Poland
Prior art keywords
antibodies
concentration
therapeutic products
therapeutic
products
Prior art date
Application number
PL05806393T
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1786830(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of PL1786830T3 publication Critical patent/PL1786830T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
PL05806393T 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty lecznicze PL1786830T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
EP05806393.4A EP1786830B1 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
PL1786830T3 true PL1786830T3 (pl) 2015-05-29

Family

ID=35996499

Family Applications (5)

Application Number Title Priority Date Filing Date
PL22178117.2T PL4108259T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL05806393T PL1786830T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty lecznicze
PL22178156.0T PL4104859T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL20200642.5T PL3805248T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL10009914.2T PL2292636T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL22178117.2T PL4108259T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL22178156.0T PL4104859T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL20200642.5T PL3805248T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL10009914.2T PL2292636T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne

Country Status (32)

Country Link
US (6) US20060051347A1 (pl)
EP (5) EP1786830B1 (pl)
JP (2) JP5210633B2 (pl)
KR (2) KR101528970B1 (pl)
CN (3) CN101056885B (pl)
AR (1) AR050641A1 (pl)
AU (1) AU2005285243C1 (pl)
BR (1) BRPI0515649B8 (pl)
CA (1) CA2577317C (pl)
DK (5) DK4104859T3 (pl)
EC (1) ECSP077282A (pl)
ES (5) ES2942574T3 (pl)
FI (4) FI4108259T3 (pl)
GT (1) GT200500254A (pl)
HU (4) HUE061899T2 (pl)
IL (2) IL181372A (pl)
LT (4) LT4104859T (pl)
MA (1) MA28991B1 (pl)
MX (2) MX2007002812A (pl)
MY (2) MY162525A (pl)
NO (1) NO333660B1 (pl)
NZ (1) NZ553239A (pl)
PE (1) PE20060816A1 (pl)
PL (5) PL4108259T3 (pl)
PT (5) PT4108259T (pl)
RU (1) RU2390524C2 (pl)
SG (1) SG177161A1 (pl)
SI (5) SI2292636T1 (pl)
TN (1) TNSN07069A1 (pl)
TW (1) TWI372630B (pl)
WO (1) WO2006031560A2 (pl)
ZA (1) ZA200701626B (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
NZ589037A (en) 2004-01-30 2011-10-28 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP1765294B1 (en) 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
EP2583744A1 (en) * 2006-03-31 2013-04-24 Genencor International, Inc. Permeate product of tangential flow filtration process
PT2628746T (pt) * 2006-04-04 2019-04-23 Chiesi Farm Spa Um processo para a concentração de um polipéptido
AU2008233173B2 (en) * 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
CA2693443C (en) * 2007-07-17 2018-02-13 F. Hoffmann-La Roche Ag Variable tangential flow filtration
EP2217624A1 (en) * 2007-11-29 2010-08-18 F. Hoffmann-La Roche AG Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
ES2406029T3 (es) * 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
BRPI0911994A2 (pt) * 2008-05-15 2015-10-20 Health L P W processo para a produção de uma fração de leite enriquecida com iga secretora, produto, e, composição.
EP2376118A1 (en) * 2008-12-09 2011-10-19 F. Hoffmann-La Roche AG Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
ES2733346T3 (es) * 2009-03-24 2019-11-28 Wyeth Llc Evaporación por membrana para generar medicamentos proteicos altamente concentrados
EP2435474A2 (en) * 2009-05-27 2012-04-04 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
ES2582581T3 (es) 2009-09-29 2016-09-13 F. Hoffmann-La Roche Ag Ajuste prefiltración de solutos tampón para la preparación de inmunoglobulinas a alta concentración
SI3133083T1 (sl) * 2009-10-01 2020-07-31 F. Hoffmann-La Roche Ag Končna filtracija v več korakih
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
PL2542257T3 (pl) 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
WO2013009686A2 (en) 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
SG11201400260TA (en) 2011-09-01 2014-03-28 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN104955479A (zh) * 2012-12-28 2015-09-30 诺和诺德股份有限公司 高温死端抗体过滤
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CA2947887C (en) 2014-05-13 2023-04-04 Amgen Inc. Process control systems and methods for use with filters and filtration processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195452A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015200691A1 (en) 2014-06-25 2015-12-30 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
EP3185996B1 (en) 2014-08-29 2022-06-15 EMD Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
ES2935333T3 (es) 2014-08-29 2023-03-06 Emd Millipore Corp Procesos para filtrar líquidos utilizando sistemas de filtración de flujo tangencial de paso único y sistemas de filtración de flujo tangencial con recirculación de retenido
CA2964786C (en) 2014-10-23 2023-10-17 Amgen Inc. Reducing the viscosity of pharmaceutical formulations with n-acetyl amino acids
EP3763384B1 (en) 2014-12-03 2024-08-28 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2017051273A1 (en) * 2015-09-22 2017-03-30 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN109195691B (zh) 2016-06-09 2022-04-29 Emd密理博公司 径向路径过滤器元件及使用其的系统和方法
KR102465761B1 (ko) * 2016-08-16 2022-11-09 젠자임 코포레이션 재조합 치료 단백질을 포함하는 유체의 처리 방법 및 상기 유체의 용도
KR102457855B1 (ko) * 2016-08-17 2022-10-25 베링거 인겔하임 인터내셔날 게엠베하 생체 분자를 함유하는 고농축 액상 제형의 제조 방법
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
WO2019199476A1 (en) * 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
IL280642B2 (en) * 2018-08-10 2025-09-01 Amgen Inc Method for preparing a pharmaceutical formulation for an antibody
EP3837273B1 (en) * 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
CA3124711A1 (en) * 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
MY191879A (en) * 2019-07-31 2022-07-18 Catalent Uk Swindon Zydis Ltd Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
EP4225770A1 (en) * 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
AU2021381439A1 (en) 2020-11-23 2023-06-22 Abec, Inc. Filtration systems,components and methods
CA3210568A1 (en) * 2021-03-08 2022-09-15 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
CA3249793A1 (en) 2022-02-25 2023-08-31 Amgen Inc. METHODS FOR PREPARING HIGH-CONCENTRATION LIQUID MEDICINAL SUBSTANCES
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
AU2023306365A1 (en) * 2022-07-12 2025-02-13 Beone Medicines I Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
CN121399243A (zh) * 2023-04-25 2026-01-23 恩泽生物科学有限公司 交替切向流过滤器在线原位清洗工艺
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (pl) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) * 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0448605A4 (en) 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
AU4589397A (en) 1997-09-22 1999-04-12 Sepragen Corporation Sequential separation of whey proteins and formulations thereof
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
EP1314437B1 (en) * 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
NZ532896A (en) 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
WO2003042344A2 (en) * 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
CA2504134C (en) * 2002-11-01 2012-03-06 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
US20040167320A1 (en) * 2003-02-24 2004-08-26 Couto Daniel E. Methods of tangential flow filtration and an apparatus therefore
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
WO2005082109A2 (en) 2004-02-26 2005-09-09 Massachusetts Institute Of Technology Solution additives for the attenuation of protein aggregation
WO2006018956A1 (ja) 2004-08-19 2006-02-23 Electronic Navigation Research Institute, An Independent Administrative Institution 誘電体レンズを用いた装置
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
US11220362B2 (en) 2017-08-16 2022-01-11 O & M Halyard, Inc. Method and system for wrapping ties in a facemask manufacturing process

Also Published As

Publication number Publication date
BRPI0515649B1 (pt) 2021-10-13
HUE067296T2 (hu) 2024-10-28
KR20120135530A (ko) 2012-12-14
EP3805248A3 (en) 2021-07-14
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
WO2006031560A2 (en) 2006-03-23
US20060051347A1 (en) 2006-03-09
PL4104859T3 (pl) 2024-08-26
NO20071432L (no) 2007-03-16
NZ553239A (en) 2009-11-27
IL216851A0 (en) 2012-01-31
US10370456B2 (en) 2019-08-06
JP2012097086A (ja) 2012-05-24
SI4104859T1 (sl) 2024-08-30
ECSP077282A (es) 2007-03-29
DK4108259T3 (da) 2024-03-11
PL4108259T3 (pl) 2024-05-13
DK3805248T5 (da) 2023-04-24
MY162525A (en) 2017-06-15
CN101056885A (zh) 2007-10-17
WO2006031560A3 (en) 2006-08-24
RU2390524C2 (ru) 2010-05-27
FI4104859T3 (fi) 2024-07-16
EP2292636A2 (en) 2011-03-09
AU2005285243C1 (en) 2012-10-25
LT3805248T (lt) 2023-04-25
JP2008512473A (ja) 2008-04-24
MA28991B1 (fr) 2007-11-01
IL181372A (en) 2012-01-31
CA2577317C (en) 2016-04-26
IL181372A0 (en) 2007-07-04
ZA200701626B (en) 2008-10-29
HUE067662T2 (hu) 2024-11-28
CA2577317A1 (en) 2006-03-23
HK1215869A1 (zh) 2016-09-23
US20090214522A1 (en) 2009-08-27
FI3805248T3 (fi) 2023-04-21
PL2292636T3 (pl) 2024-03-11
AR050641A1 (es) 2006-11-08
EP3805248B1 (en) 2023-01-18
HUE065025T2 (hu) 2024-04-28
PE20060816A1 (es) 2006-09-02
FI4108259T3 (fi) 2024-09-10
US12371510B2 (en) 2025-07-29
PL3805248T3 (pl) 2023-05-22
PT4108259T (pt) 2024-03-07
DK1786830T3 (en) 2015-01-19
CN102911268A (zh) 2013-02-06
AU2005285243B2 (en) 2012-03-08
MX342788B (es) 2016-10-12
SI1786830T1 (sl) 2015-03-31
US20070237762A1 (en) 2007-10-11
DK4104859T3 (da) 2024-07-08
FI2292636T3 (fi) 2024-01-12
KR20070109975A (ko) 2007-11-15
EP4104859B1 (en) 2024-04-17
JP5426641B2 (ja) 2014-02-26
LT4104859T (lt) 2024-07-10
SG177161A1 (en) 2012-01-30
ES2983099T3 (es) 2024-10-22
SI3805248T1 (sl) 2023-05-31
NO333660B1 (no) 2013-08-05
LT4108259T (lt) 2024-04-10
US11767370B2 (en) 2023-09-26
KR101528970B1 (ko) 2015-06-15
ES2968070T3 (es) 2024-05-07
CN101056885B (zh) 2015-08-26
KR101528970B9 (ko) 2022-12-09
MY150549A (en) 2014-01-30
EP2292636A3 (en) 2013-05-01
EP4108259B1 (en) 2024-01-03
SI4108259T1 (sl) 2024-04-30
ES2528541T3 (es) 2015-02-10
CN104961797B (zh) 2020-12-25
US20140370003A1 (en) 2014-12-18
EP1786830B1 (en) 2014-11-12
ES2942574T3 (es) 2023-06-02
CN104961797A (zh) 2015-10-07
PT3805248T (pt) 2023-04-05
DK2292636T3 (da) 2024-01-15
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
TNSN07069A1 (en) 2008-06-02
EP2292636B1 (en) 2023-10-18
DK3805248T3 (da) 2023-04-03
EP2292636B9 (en) 2024-01-03
BRPI0515649A (pt) 2008-07-29
SI2292636T1 (sl) 2024-02-29
TWI372630B (en) 2012-09-21
HK1101249A1 (en) 2007-10-12
BRPI0515649B8 (pt) 2021-11-03
EP4104859A1 (en) 2022-12-21
PT1786830E (pt) 2015-02-05
AU2005285243A1 (en) 2006-03-23
JP5210633B2 (ja) 2013-06-12
MX2007002812A (es) 2007-05-16
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
US20230074486A1 (en) 2023-03-09
ES2975166T3 (es) 2024-07-03
EP4108259A1 (en) 2022-12-28
TW200612989A (en) 2006-05-01
EP1786830A2 (en) 2007-05-23
PT4104859T (pt) 2024-07-02
HUE061899T2 (hu) 2023-08-28

Similar Documents

Publication Publication Date Title
TWI372630B (en) Process for concentration of antibodies and therapeutic products thereof
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
EP1814967A4 (en) APPARATUS FOR THERMOTRATING PARTICULATE MATERIALS
IL178593A (en) Specific antibodies of fcγriib and methods for their use
GB0521942D0 (en) Methods and software for analysis of research publications
ZA200703013B (en) Apparatus for heat treatment of particulate materials
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1815226A4 (en) DEVICE AND METHOD FOR PURIFYING BIOLOGICAL SUBSTANCES
GB2445651B (en) Well treatment products and methods of using them
EP1740692A4 (en) METHOD AND DEVICE FOR QUANTITATIVE ASSAYS
PT1919290E (pt) Métodos e produtos para tratamento de doenças
EP1767565A4 (en) PROCESS FOR CLEANING OLIGOANILINES AND OLIGOANILINES
ZA200607471B (en) Materials and methods for treatment of allergic disease
GB0400394D0 (en) Biosensor and method of manufacture
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
ZA200704725B (en) Product and method of treatment
IL179209A0 (en) Small molecules for treatment of hypercholesterolemia and related diseases
GB0515649D0 (en) Method and apparatus for treatment of preforms
ZA200703614B (en) Novel composition and methods for the treatment of immune related diseases